Gan & Lee Pharmaceuticals Co. Ltd. has described protein cereblon (CRBN) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.

Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer.

Researchers at Chongqing Pharmaceutical Research Institute Co. Ltd. and Yaopharma Co. Ltd. have identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity, type 2 diabetes and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Scientists at the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences have synthesized nonstructural protein 14 (NSP14) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.

Inflamax Pharmaceuticals (Guangzhou) Co. Ltd. has disclosed proprotein convertase subtilisin/kexin-type 6 (PCSK6; PACE4; PC7A) inhibitors reported to be useful for the treatment of osteoarthritis.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Inmed Pharmaceuticals Inc. has divulged cannabinoid CB1 and/or CB2 receptor modulators reported to be useful for the treatment of neurodegeneration and age-related macular degeneration.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has identified radiolabeled or nonradiolabeled compounds acting as fibroblast activation protein-α (FAPα) inhibitors reported to be useful for the diagnosis and treatment of cancer.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of inflammatory disorders, immunological disorders, viral infections and cancer.